Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08. Januar 2025 16:05 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
07. Januar 2025 16:15 ET
|
Solid Biosciences Inc.
- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac manifestations of Friedreich’s ataxia -- Dual route of administration enables direct...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06. Januar 2025 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences Added to the Nasdaq Biotechnology Index
23. Dezember 2024 16:05 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies
04. Dezember 2024 08:00 ET
|
Solid Biosciences Inc.
- Solid Biosciences to collaborate with Mayo Clinic’s genetic cardiology disease laboratory - - Solid to receive exclusive worldwide licenses to AAV-based Suppression-Replacement gene therapy...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03. Dezember 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
Solid Biosciences to Participate at Upcoming Investor Conferences
26. November 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences to Present at the Jefferies London Healthcare Conference
14. November 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates
06. November 2024 16:05 ET
|
Solid Biosciences Inc.
- Duchenne: Dosing completed for first three patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all patients with no SAEs observed; initial three patient data expected Q1...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04. November 2024 08:00 ET
|
Solid Biosciences Inc.
CHARLESTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...